Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $17.66B |
| Gross Profit (TTM) | $8.12B |
| EBITDA | $2.42B |
| Operating Margin | 14.00% |
| Return on Equity | 10.20% |
| Return on Assets | 4.07% |
| Revenue/Share (TTM) | $18.55 |
| Book Value | $13.66 |
| Price-to-Book | 1.92 |
| Price-to-Sales (TTM) | 1.43 |
| EV/Revenue | 1.558 |
| EV/EBITDA | 9.14 |
| Quarterly Earnings Growth (YoY) | 61.40% |
| Quarterly Revenue Growth (YoY) | 0.50% |
| Shares Outstanding | $977.43M |
| Float | $976.62M |
| % Insiders | 0.00% |
| % Institutions | 5.42% |
Volatility is currently contracting
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
September 3, 2026 FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer.
August 27, 2026 The solution combines Philips' high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imrico r' s exclusive portfolio of systems and consumables for MR-guided cardiac interventions. Amsterdam, the Netherlands – August 27, 2026: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR.
August 26, 2026 Philips receives up to US$33.7 million award from ARPA-H to expand access to AI-enabled robotic stroke care, supporting the program's goal of expanding access to specialized interventions Philips will collaborate with Johns Hopkins University and Boston University to develop technologies for remote and increasingly automated endovascular procedures Building on Philips' leadership in image-guided therapy and the Azurion platform, the work lays the foundation for a future interventional suite that integrates robotics, AI-enabled automation and smart devices into a single clinical workflow Cambridge, MA, USA and Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received an up to US$33.7 million award under the Advanced Research Projects Agency for Health (ARPA-H, an agency within the U.S. Department of Health and Human Services (HHS)) Autonomous Interventions and Robotics (AIR) program, led by Dr. Ileana Hancu, to advance AI-enabled robotic procedure automation for stroke care. Working with Johns Hopkins University, Boston University, and Dr. J Mocco of Weill Cornell Medicine, Philips will develop technologies for remote-assisted and increasingly automated endovascular procedures, helping expand access to advanced stroke care.
August 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note (EMTN) program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard.
Philips' largest shareholder Exor , the investment arm of Italy's Agnelli family, has extended its agreement with the health technology firm, giving it the flexibility to increase its stake to up to 22%, the companies said on Tuesday.
August 6, 2026 New collaborations expand wearable and out-of-hospital monitoring capabilities, helping support continuous patient visibility from admission through recovery at home Amsterdam, Netherlands. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare, further expanding its open monitoring ecosystem.
The "Share the Care Connector" helps turn good intentions into real, meaningful support and connection for new moms during the postpartum period, when they need it most. CAMBRIDGE, Mass.
PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PHG and any ticker you trade — then tracks every position and per-strategy win rate.
